These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

310 related articles for article (PubMed ID: 15765377)

  • 21. Treatment of non-Hodgkin's lymphoma (NHL) with radiolabeled antibodies (mAbs).
    DeNardo GL
    Semin Nucl Med; 2005 Jul; 35(3):202-11. PubMed ID: 16098294
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Development of anti-MUC1 di-scFvs for molecular targeting of epithelial cancers, such as breast and prostate cancers.
    Albrecht H; Denardo GL; Denardo SJ
    Q J Nucl Med Mol Imaging; 2007 Dec; 51(4):304-13. PubMed ID: 17464275
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Antibody pretargeting advances cancer radioimmunodetection and radioimmunotherapy.
    Goldenberg DM; Sharkey RM; Paganelli G; Barbet J; Chatal JF
    J Clin Oncol; 2006 Feb; 24(5):823-34. PubMed ID: 16380412
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Combined radioimmunotherapy and chemotherapy of breast tumors with Y-90-labeled anti-Her2 and anti-CEA antibodies with taxol.
    Crow DM; Williams L; Colcher D; Wong JY; Raubitschek A; Shively JE
    Bioconjug Chem; 2005; 16(5):1117-25. PubMed ID: 16173788
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Status of radioimmunotherapy in the new millennium.
    Imam SK
    Cancer Biother Radiopharm; 2001 Jun; 16(3):237-56. PubMed ID: 11471488
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A new radiopharmaceutical compound (131I-PR81) for radioimmunotherapy of breast cancer: labeling of antibody and its quality control.
    Mohammadnejad J; Rasaee MJ; Babaei MH; Paknejad M; Zahir MH; Salouti M; Rajabi AB; Mazidi M
    Hum Antibodies; 2010; 19(4):79-88. PubMed ID: 21178279
    [TBL] [Abstract][Full Text] [Related]  

  • 27. High-dose radioimmunotherapy combined with fixed, low-dose paclitaxel in metastatic prostate and breast cancer by using a MUC-1 monoclonal antibody, m170, linked to indium-111/yttrium-90 via a cathepsin cleavable linker with cyclosporine to prevent human anti-mouse antibody.
    Richman CM; Denardo SJ; O'Donnell RT; Yuan A; Shen S; Goldstein DS; Tuscano JM; Wun T; Chew HK; Lara PN; Kukis DL; Natarajan A; Meares CF; Lamborn KR; DeNardo GL
    Clin Cancer Res; 2005 Aug; 11(16):5920-7. PubMed ID: 16115934
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical radioimmunotherapy.
    Knox SJ; Meredith RF
    Semin Radiat Oncol; 2000 Apr; 10(2):73-93. PubMed ID: 10727597
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Radioimmunodetection and radioimmunotherapy of breast cancer.
    Riva P; Franceschi G; Gentile R; Riva N; Casi M
    Tumori; 1997; 83(2):552-7. PubMed ID: 9226019
    [No Abstract]   [Full Text] [Related]  

  • 30. Perspectives on metals-based radioimmunotherapy (RIT): moving forward.
    White JM; Escorcia FE; Viola NT
    Theranostics; 2021; 11(13):6293-6314. PubMed ID: 33995659
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Enhancement of the therapeutic index: from nonmyeloablative and myeloablative toward pretargeted radioimmunotherapy for metastatic prostate cancer.
    DeNardo SJ; Richman CM; Albrecht H; Burke PA; Natarajan A; Yuan A; Gregg JP; O'Donnell RT; DeNardo GL
    Clin Cancer Res; 2005 Oct; 11(19 Pt 2):7187s-7194s. PubMed ID: 16203820
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Advances in cancer therapy with radiolabeled monoclonal antibodies.
    Goldenberg DM; Sharkey RM
    Q J Nucl Med Mol Imaging; 2006 Dec; 50(4):248-64. PubMed ID: 17043623
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Current status and perspectives in alpha radioimmunotherapy.
    Chérel M; Davodeau F; Kraeber-Bodéré F; Chatal JF
    Q J Nucl Med Mol Imaging; 2006 Dec; 50(4):322-9. PubMed ID: 17043629
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Treatment of infection with radiolabeled antibodies.
    Dadachova E; Casadevall A
    Q J Nucl Med Mol Imaging; 2006 Sep; 50(3):193-204. PubMed ID: 16868533
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Recombinant bispecific monoclonal antibodies prepared by the dock-and-lock strategy for pretargeted radioimmunotherapy.
    Sharkey RM; Rossi EA; McBride WJ; Chang CH; Goldenberg DM
    Semin Nucl Med; 2010 May; 40(3):190-203. PubMed ID: 20350628
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Radioimmunotargeting: diagnosis and therapeutic use].
    Vuillez JP
    Bull Cancer; 2000 Nov; 87(11):813-27. PubMed ID: 11125290
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Radioimmunotherapy of solid tumors: the promise of pretargeting strategies using bispecific antibodies and radiolabeled haptens.
    Reilly RM
    J Nucl Med; 2006 Feb; 47(2):196-9. PubMed ID: 16455623
    [No Abstract]   [Full Text] [Related]  

  • 38. High-dose radioimmunotherapy combined with extracorporeal depletion in a syngeneic rat tumor model: evaluation of toxicity, therapeutic effect, and tumor model.
    Mårtensson L; Nilsson R; Ohlsson T; Sjögren HO; Strand SE; Tennvall J
    Cancer; 2010 Feb; 116(4 Suppl):1043-52. PubMed ID: 20127949
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Radioimmunotherapy of MCF7 breast cancer cell line with 131I-PR81 monoclonal antibody against MUC1: comparison of direct and indirect radioiodination methods.
    Mohammadnejad J; Rasaee MJ; Babaei MH; Paknejad M; Hasan ZM; Salouti M; Gandomkar M; Sadri K
    Hum Antibodies; 2010; 19(1):15-25. PubMed ID: 20555127
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Factors influencing the pharmacokinetics, dosimetry, and diagnostic accuracy of radioimmunodetection and radioimmunotherapy of carcinoembryonic antigen-expressing tumors.
    Behr TM; Sharkey RM; Juweid MI; Dunn RM; Ying Z; Zhang CH; Siegel JA; Gold DV; Goldenberg DM
    Cancer Res; 1996 Apr; 56(8):1805-16. PubMed ID: 8620497
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.